# Nutex Health Inc.: Form 10-K for the period ended Dec 31, 2016

- Company: [Nutex Health Inc.](/companies/nutx.md) (CIK 1479681)
- Form: 10-K
- Filed: 2017-04-17
- Accepted by EDGAR: Apr 17, 2017, 16:29 ET
- Period: 2016-12-31
- Accession: 0001211524-17-000046
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1479681/000121152417000046/f2016igambitform10kdraft4152.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479681/000121152417000046/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2016-01-01 to 2016-12-31 | −$448.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2016-01-01 to 2016-12-31 | −$2.6k | us-gaap:InterestExpense |
| Net income | 12 months, 2016-01-01 to 2016-12-31 | −$7.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2016-01-01 to 2016-12-31 | −$0.19 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 12 months, 2016-01-01 to 2016-12-31 | 39,687,747 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2016-01-01 to 2016-12-31 | −$274.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2016-12-31 | $10.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $507.9k | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $510.8k | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $6.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-12-31 | $6.4m | us-gaap:Liabilities |

## Business

As filed, 10,345 characters.

### HISTORY

We were incorporated in the State of Delaware under the name BigVault.com Inc.

on April 13, 2000. On April 18, 2000, we merged with BigVault.com, Inc., a New York

corporation with which we were affiliated. We survived the merger, and on December 19,

2000 changed our name to bigVAULT Storage Technologies, Inc. At that time we were

in the business of providing remote, internet-based storage vaulting services and related

ancillary services to end users and resellers (the “Vault Business”).

On February 28, 2006 we sold all of our assets to Digi-Data Corporation

(“DDC”), an unrelated third party, pursuant to the terms of an Asset Purchase Agreement

dated December 21, 2005 (the “APA”), a copy of which is filed herewith as an exhibit.

As consideration for our transfer of assets under the APA, DDC paid certain of our

liabilities and agreed to make certain quarterly and annual revenue sharing payments to

us, as is further described below. Mr. Salerno and Ms. Luqman accepted employment

with DDC in senior management positions post closing, and continued to work for DDC

until February 2009. As of March 1, 2009 Mr. Salerno and Ms. Luqman returned to their

full time management roles with the Company.

On April 5, 2006, we changed our name to iGambit Inc.

On October 1, 2009, we acquired the assets of Jekyll Island Ventures, Inc., a New

York corporation doing business as Gotham Photo Company (“Jekyll”) through our

wholly owned subsidiary Gotham Innovation Lab, Inc., a New York corporation

(“Gotham”).

On November 4, 2015, we consummated the acquisition of Wala, Inc. doing

business as ArcMail Technology (ArcMail) in accordance with a Stock Purchase

Agreement (the “ArcMail Purchase Agreement”) by and among Wala, Inc. doing

business as ArcMail Technologies (“ArcMail”), Rory T. Welch (the “Seller”) and the

Company. Pursuant to the Stock Purchase, the total consideration to be paid for the outstanding

capital stock of ArcMail is 11,500,000 shares of the Company’s Common stock. 10,500,000

shares of iGambit’s Common stock to the Seller, and/or Seller’s designees at Closing and

the Holdback Amount of 1,000,000 shares of the iGambit’s Common stock to be held in

Escrow and paid to the Seller on later of (i) the first (1st) anniversary of completion of the

first audit of Purchaser after the Closing, or (ii) that date which is twelve (12) months

from the Closing, provided that in the event iGambit or the Purchaser has any claims for

indemnification against the Seller under the Purchase Agreement, Purchaser shall

continue to withhold the portion of the Holdback Amount subject to such claims until the

parties fully and finally resolve such claims.

The ArcMail Purchase Agreement was disclosed on the Company’s current report

on Form 8-K filed on November 10, 2015.

On November 5, 2015, through our wholly owned subsidiary Gotham Innovation

Lab, Inc. (“Gotham”), we completed the sale of certain assets of Gotham to VHT Inc.

(“VHT”) in accordance with an Asset Purchase Agreement (the “VHT Purchase

Agreement”) by and between Gotham and VHT. Pursuant to the Purchase Agreement

the Company received $600,000 in consideration, $400,000 of the consideration was

received at closing and the remaining $200,000 portion of the consideration is subject to

twelve (12) equal monthly payments beginning January 2016. The sale included certain

of the assets of the Gotham, including the Elliman customer agreement, all customer

accounts, all vendor agreements and all the intellectual property.

The VHT Purchase Agreement was disclosed on the Company’s current report on

Form 8-K filed on November 11, 2015.

On February 14, 2017, we consummated the acquisition of HubCentrix, Inc.

(HubCentrix) in accordance with a Stock Exchange Agreement (the “Exchange

Agreement”) by and among HubCentrix, Jerry Robinson, Mary-Jo Robinson, Kathleen

Shepherd, Edwin Shepherd, Nora Minor,,and Sandra Gacio (the “Hub Shareholders”) and

the Company. Pursuant to the Exchange Agreement, the total consideration to be paid for

the outstanding capital stock of HubCentrix is 15,000,000 shares of the Company’s

Common stock. 13,500,00 shares of iGambit’s Common stock to the Hub Shareholders at

Closing and the Holdback Amount of 1,500,000 shares of the iGambit’s Common stock

to be held restricted and paid to the Seller on later of (i) the first (1st) anniversary of

completion of the first audit of Purchaser after the Closing, or (ii) that date which is

twelve (12) months from the Closing, provided that in the event the Company has any claims for indemnification against the HubCentrix under the Exchange Agreement, the

Company shall continue to withhold the portion of the Holdback Amount subject to such

claims until the parties fully and finally resolve such claims.

The HubCentrix Exchange Agreement was disclosed on the Company’s current

report on Form 8-K filed on February 15, 2017.

On March 27, 2017 we changed the name of HubCentrix, Inc. to HealthDatix, Inc.

On April 5, 2017, the Company, through its wholly owned subsidiary

HealthDatix, Inc. (“HealthDatix”) consummated the acquisition of certain assets of the

CyberCare Health Network Division from EncounterCare Solutions Inc. (ECSL) in

accordance with an Asset Purchase Agreement (the “Agreement”) by and among,

HealthDatix, ECSL and the Company. Pursuant to the Agreement, ECSL will sell,

convey, transfer and assign to HealthDatix certain assets (the “Assets”), and HealthDatix

will purchase and accept from the ECSL all right, title and interest in and to the Assets in

exchange for sixty million 60,000,000 shares of restricted common stock of iGambit.

The ECSL Agreement was disclosed on the Company’s current report on Form 8-

K filed on April 6, 2017.

### OUR COMPANY

### Introduction

Previously we were a company focused on the technology markets. We have

tailored our strategy to focus on pursuing specific medical technology strategies and

objectives.

Presently we have one operating subsidiary, Wala, Inc. doing business as ArcMail

Technology (ArcMail) which was purchased on November 4, 2015. ArcMail is in the

business of providing simple, secure and cost-effective email and enterprise archiving

and management solutions to businesses of all sizes across a wide range of vertical

markets. On March 7, 2017 we entered into a Letter of Intent (LOI) to sell substantially

all the assets of ArcMail. The LOI has certain binding and non-binding obligations,

including the acquisition consideration which is subject to adjustment and the transaction

is subject to various conditions to closing, including satisfactory completion of due

diligence, approval of the Company’s shareholders, if required, and definitive

documentation. There can be no assurance that the transactions contemplated by the LOI

will be consummated.

As a result of the entry into the LOI, the generally accepted

accounting principles require us to present the ArcMail financial information as

discontinued operations. See financial disclosures below.

Our primary focus is the expansion of our newly acquired medical technology

business HealthDatix Inc.

### HealthDatix

### Products and Services

HealthDatix is an end to end Software-as-a-Service solution that manages,

reports, and analyzes critical data, enabling healthcare organizations to deliver positive

patient outcomes. We offer a fully-hosted cloud service for healthcare providers to

conduct the Medicare Annual Wellness Visit (AWV) program to their Medicare patients

providing the patient with a 5-10 year Personalized Preventive Plan and physician reports

that meet all Medicare audit requirements. The AWV is a program that allows a

physician to identify those patients that have 2+ chronic conditions that require additional

screening and management.

### Competitive Comparison

HealthDatix AWV solution is built on a simple and flexible design that gives

customers ownership and control over their data and offers a single comprehensive

solution for Medicare compliance and data retention. HealthDatix primary competitors

include AWV360 and AWVTotal Solutions. Their primary focus is on just the primary

care physicians and not operating through a downstream channel program

HealthDatix competes effectively against its primary competitors by providing a

simple and scalable application and world-class customer support. HealthDatix’s primary

competitive differentiation includes:

- Simple User Interface
- Efficient Reporting

Proprietary algorithm to generate Medicare required patient and practice

reporting

- HIPAA complaint
- Fully automated and easy user data capture
- Channel Program
- First Class Customer Service

Support is provided at our U.S. headquarters by an experienced technical

team

### Future Products and Services

HeathDatix’s product strategy is to provide additional products that will support

the patients that have been identified through the program to require additional chronic

care management with a medical wearable that will allow ease of use for the patient and

effective tracking and management by the physician through our developed chronic care

management solution.

### Customers

HealthDatix operates by bringing on Channel Partners to sell the service to

primary care Physicians, ACOs and Managed Care Practices. We currently have 5

Channel Partners with extensive sales arms through established healthcare technology

companies.

### Expansion Summary

HealthDatix objective is to be a market leader in providing a world class AWV

software application as well as expand our offering to current and new channel partners

with our new chronic care management and medical wearable technology acquired

pursuant to the recent ECSL transaction.

### Employees

We presently have 7 total employees all of which are full-time for operations and

11 full time employees from discontinued operations.

### OUR CORPORATE INFORMATION

Our principal offices are located at 1050 W. Jericho Turnpike, Suite A,

Smithtown, New York, 11787. Our telephone number is (631) 670-6777 and our fax

number is (631) 670-6780. We currently operate two corporate websites that can be

found at www.igambit.com, and www.healthdatix.com (the information on the foregoing

websites does not form a part of this report).

## Properties

As filed, 1,737 characters.

Our corporate executive office is located in Smithtown, New York, where we

lease approximately 1000 square feet of office space. Monthly lease payments are

approximately $1,660. The lease is for a term of two (2) years commencing on March 1,

2017 and ending on February 28, 2019. The lease contains annual escalations of 2% of

the annual rent.

Our HealthDatix operations are located in St. Petersbug, Florida where we lease

where office suites with furniture and equipment in the TecGarage shared coworking

incubator office building. Monthly lease payments are $695 paid on a month to month

basis.

Our ArcMail discontinued operations are located in Shreveport, Louisiana, where

we lease approximately 2,989 rentable square feet to be used as office space and 178

rentable square feet to be used as storage space, for a total of 3,167 rentable square feet.

space. The lease is for a term of forty five (35) months beginning February 1, 2015 and

ending October 31, 2018 payable monthly in the following manner:

02-01-15 through 04-30-15

$ 0.00/mth.

05-01-15 through 04-30-16

$ 3,404.19/mth. ($13.25/s.f/yr.-office; $7.00/s.f.Iyr.-storage)

05-01-16 through 04-30-17

$ 3,528.73/mth. ($13.75/s.f/yr.--office; $7.00/s.f./yr.-storage)

05-01-17 through 10-31-18

$ 3,653.27/mth. ($14.25/s.f/yr.--office; $7.00/s.f./yr.-storage)

Our leased properties are suitable for their respective uses and are, in general,

adequate for our present needs. Our properties are subject to various federal, state, and

local statutes and ordinances regulating their operations. Management does not believe

that compliance with such statutes and ordinances will materially affect our business,

financial condition, or results of operations.

## Legal proceedings

As filed, 279 characters.

From time-to-time, the Company is involved in various civil actions as part of its normal

course of business. The Company is not a party to any litigation that is material to

ongoing operations as defined in Item 103 of Regulation S-K as of the period ended

December 31, 2017.

## Management's discussion and analysis

As filed, 19,924 characters.

### CONDITION AND RESULTS OF OPERATIONS

### CRITICAL ACCOUNTING POLICIES

Our management’s discussion and analysis of our financial condition and results

of operations are based on our financial statements, which have been prepared in

accordance with accounting principles generally accepted in the United States of

America. The preparation of financial statements may require us to make estimates and

assumptions that may affect the reported amounts of assets and liabilities and the related

disclosures at the date of the financial statements. We do not currently have any estimates

or assumptions where the nature of the estimates or assumptions is material due to the

levels of subjectivity and judgment necessary to account for highly uncertain matters or

the susceptibility of such matters to change or the impact of the estimates and assumptions on financial condition or operating performance is material, except as described below.

### Principles of Consolidation

The consolidated financial statements include the accounts of the Company and

its wholly-owned subsidiaries Wala, Inc. and Gotham Innovation Lab, Inc. All

intercompany accounts and transactions have been eliminated.

### Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted

accounting principles requires management to make estimates and assumptions that affect

the reported amounts of assets and liabilities and disclosure of contingent assets and

liabilities at the date of the consolidated financial statements and the reported amounts of

revenues and expenses during the period. Actual results could differ from those estimates.

### Long-Lived Assets

We assess the valuation of components of its property and equipment and other

long-lived assets whenever events or circumstances dictate that the carrying value might

not be recoverable. We base our evaluation on indicators such as the nature of the assets,

the future economic benefit of the assets, any historical or future profitability

measurements and other external market conditions or factors that may be present. If such

factors indicate that the carrying amount of an asset or asset group may not be

recoverable, we determine whether an impairment has occurred by analyzing an estimate

of undiscounted future cash flows at the lowest level for which identifiable cash flows

exist. If the estimate of undiscounted cash flows during the estimated useful life of the

asset is less than the carrying value of the asset, we recognize a loss for the difference

between the carrying value of the asset and its estimated fair value, generally measured

by the present value of the estimated cash flows.

### Revenue Recognition

We recognize revenue from product sales when the following four revenue

recognition criteria are met: persuasive evidence of an arrangement exists, an equipment

order has been placed with the vendor, the selling price is fixed or determinable, and

collectability is reasonably assured. Revenues from maintenance contracts covering

multiple future periods are recognized during the current periods and deferred revenue is

recorded for future periods and classified as current or noncurrent, depending on the

terms of the contracts.

### Deferred Revenue

Deposits from customers are not recognized as revenues, but as liabilities, until

the following conditions are met: revenues are realized when cash or claims to cash

(receivable) are received in exchange for goods or services or when assets received in

such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from our support and maintenance services, we recognize such revenues when services are completed and billed. We have received deposits from various customers that have been recorded as deferred revenue in the amount of $1,092,388 and $1,190,270 as of the years ended December 31, 2016 and 2015, respectively.

### Accounts Receivable

We analyze the collectability of accounts receivable from continuing operations

each accounting period and adjust our allowance for doubtful accounts accordingly. A

considerable amount of judgment is required in assessing the realization of accounts

receivables, including the creditworthiness of each customer, current and historical

collection history and the related aging of past due balances. We evaluate specific

accounts when we become aware of information indicating that a customer may not be

able to meet its financial obligations due to deterioration of its financial condition, lower

credit ratings, bankruptcy or other factors affecting the ability to render payment.

Allowance for doubtful accounts was $8,345 at December 31, 2016 and 2015,

respectively. Bad debt expense of $0 and $5,971 was charged to operations for the years

ended December 31, 2016 and 2015, respectively.

### Goodwill and Intangible Assets

Goodwill represents the excess of liabilities assumed over assets acquired of

ArcMail and the fair market value of the common shares we issued for the acquisition of

ArcMail. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”),

the goodwill is not being amortized, but instead will be subject to an annual assessment

of impairment by applying a fair-value based test, and will be reviewed more frequently

if current events and circumstances indicate a possible impairment. An impairment loss is

charged to expense in the period identified. If indicators of impairment are present and

future cash flows are not expected to be sufficient to recover the asset’s carrying amount,

an impairment loss is charged to expense in the period identified. A lack of projected

future operating results from ArcMail’s operations may cause impairment. During the

year ended December 31, 2016, goodwill was reallocated to intangible assets acquired as

follows:

Workforce

138,783

Non-compete

145,315

Customer relations

3,357,756

3,641,854

Goodwill

3,063,303

$ 6,705,157

In connection with management’s decision to sell Arcmail, we recorded an

impairment charge to discontinued operations of $6,263,320, and amortization of

$441,837 was charged to discontinued operations during the year ended December 31,

2016.

### Stock-Based Compensation

We account for our stock-based awards granted under our employee

compensation plan in accordance with ASC Topic No. 718-20, *Awards Classified as*

*Equity,* which requires the measurement of compensation expense for all share-based

compensation granted to employees and non-employee directors at fair value on the date

of grant and recognition of compensation expense over the related service period for

awards expected to vest. We use the Black-Scholes option pricing model to estimate the

fair value of our stock options and warrants. The Black-Scholes option pricing model

requires the input of highly subjective assumptions including the expected stock price

volatility of the Company’s common stock, the risk free interest rate at the date of grant,

the expected vesting term of the grant, expected dividends, and an assumption related to

forfeitures of such grants. Changes in these subjective input assumptions can materially

affect the fair value estimate of the Company’s stock options and warrants.

#### Options

In 2006, we adopted the 2006 Long-Term Incentive Plan (the "2006 Plan").

Awards granted under the 2006 Plan have a ten-year term and may be incentive stock

options, non-qualified stock options or warrants. The awards are granted at an exercise

price equal to the fair market value on the date of grant and generally vest over a three or

four year period. The Plan expired on December 31, 2009, therefore as of December 31,

2015, there was no unrecognized compensation cost related to non-vested share-based

compensation arrangements granted under the 2006 plan.

The 2006 Plan provided for the granting of options to purchase up to 10,000,000

shares of common stock. 8,146,900 options have been issued under the plan to date of

which 7,157,038 have been exercised and 692,962 have expired to date. There were

296,900 options outstanding under the 2006 Plan on its expiration date of December 31,

2009\. All options issued subsequent to this date were not issued pursuant to any plan.

#### Warrants

In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding

compensatory warrants to two consultants entitling the holders to purchase a total of

275,000 shares of our common stock at an average exercise price of $0.94 per share.

Warrants to purchase 25,000 shares of common stock vest upon 6 months after the

Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2

years after the Company engages in an IPO. Warrants to purchase 250,000 shares of

common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each

of the following three anniversaries of the date of issuance, have exercise prices ranging

from $0.50 per share to $1.15 per share, and expire on June 1, 2019. The issuance of the

compensatory warrants was not submitted to our shareholders for their approval.

### Convertible Debenture

During the year ended December 31, 2016, we issued convertible debentures to

two individuals. The debentures are convertible into 50,000 shares of common stock for

up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively.

The debentures mature on the earlier of the closing of a subsequent financing event by

the Company resulting in gross proceeds of at least $10,000,000 or three years from the

date of issuance. The debentures bear interest at a rate of 10% and is deferred until 2017.

A beneficial conversion feature was not recorded as the fair market value of the

Company’s common stock was less than the exercise prices at the dates of issuance and

through the end of the year.

### Income Taxes

We follow Accounting Standards Codification subtopic 740, *Income Taxes (“*ASC

740”) which requires the recognition of deferred tax liabilities and assets for the expected

future tax consequences of events that have been included in the financial statements or

tax returns. Under such method, deferred tax assets and liabilities are recognized for the

future tax consequences attributable to differences between the financial statement

carrying amounts of existing assets and liabilities and their respective tax bases using

enacted tax rates in effect for the year in which the differences are expected to reverse.

Deferred taxes are classified as current or non-current, depending on the classification of

the assets and liabilities to which they relate.

### MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

### CONDITION AND RESULTS OF OPERATIONS

### Introduction

iGambit is a company focused on the medical technology markets. Our primary

focus is the expansion of our newly acquired medical technology business HealthDatix

Inc.

### Year Ended December 31, 2016 as Compared to Year Ended December 31, 2015

***Assets.*** At December 31, 2016, we had $507,932 in current assets and $510,835

in total assets, compared to $7,634,620 in current assets and $7,637,996 in total assets as

of December 31, 2015. The decrease in total assets was primarily due to a decrease in

assets from discontinued operations as a result of impairment of goodwill and intangible

assets.

***Liabilities.*** At December 31, 2016, we had total liabilities of $6,380,260

compared to $6,076,680 at December 31, 2015. Our total liabilities at December 31, 2016

consisted of current liabilities including accounts payable and accrued expenses of

$356,005, amounts due to related parties of $508, convertible debentures of $50,000 and

labilities from discontinued operations of $5,905,666, whereas our total liabilities at

December 31, 2015 consisted of current liabilities including accounts payable of

$168,971, amounts due to related parties of $2,043, and liabilities from discontinued

operations of $5,905,666. We had no long term liabilities for the year ended December

31, 2016. The increase in liabilities was primarily due to an increase in accounts payable

and accrued interest

***Stockholders’ Equity (Deficiency).*** Our Stockholders’ Deficiency was

$(5,869,425) at December 31, 2016 compared to Stockholders’ Equity of $1,561,316 at

December 31, 2015 This decrease was due to an increase in accumulated deficit from

$(2,798,390) at December 31, 2015 to $(10,230,631) at December 31, 2016 resulting

from net loss from continuing operations of $(451,060) and a net loss from discontinued

operations of $(6,981,181) primarily due to impairment of goodwill and intangible assets.

***Net Income (Loss).*** We had a loss from continuing operations of $(451,060) and

$(536,130) for the years ended December 31, 2016 and December 31, 2015, respectively,

and a loss from discontinued operations of $(6,981,181) compared to income from

discontinued operations of $619,939 for the year ended December 31, 2016 and

December 31, 2015, respectively.

***General and Administrative Expenses.*** General and Administrative Expenses

decreased to $448,595 for the year ended December 31, 2016 from $532,988 for the year

ended December 31, 2015. For the year ended December 31, 2016 our General and

Administrative Expenses consisted of corporate administrative expenses of $90,617, legal

and accounting fees of $115,660, payroll expenses of $91,155, Directors and Officers

Insurance of $10,053 employee benefits expenses of $24,217 (medical and life insurance)

filing fees of $11,779, financing expense of $10,000, and $95,114 in marketing and

finder’s fees. For the year ended December 31, 2015 our General and Administrative

Expenses consisted of corporate administrative expenses of $98,085, legal and

accounting fees of $124,555, payroll expenses of $111,838, Directors and Officers

Insurance of $42,206, employee benefits expenses of $20,790 (medical and life

insurance), filing fees of $12,489, and $123,025 in in marketing and finder’s fees.

Therefore the decreases from the year ended December 31, 2015 to the year ended

December 31, 2016 relate primarily to a decrease in payroll, legal and professional fees

and in marketing and finder’s fees. In 2017 we anticipate an increase in General

Administrative Expenses associated with the HealthDatix acquisition.

### LIQUIDITY AND CAPITAL RESOURCES

### General

As reflected in the accompanying consolidated financial statements, at December

31, 2016, we had $10,522 of cash and stockholders’ deficiiency of $(5,869,425). At

December 31, 2015, we had $122,291 of cash and stockholders’ equity of $1,561,316.

Our primary capital requirements in 2017 are likely to arise from the expansion of

our HealthDatix operations, It is not possible to quantify those costs at this point in time,

in that they depend on HealthDatix’s business opportunities and the state of the overall

economy. We anticipate raising capital in the private markets to cover any such costs,

though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales

volume, and in our ability to raise additional funds, there can be no assurances that we

will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the

foreseeable future. We believe we have enough capital to fund our present operations.

### Cash Flow Activity

Net cash used in operating activities was $274,223, for the year ended December

31, 2016, compared to net cash provided by operating activities of $44,907 for the year

ended December 31, 2015. Net cash used in continuing operating activities was

$142,092 for the year ended December 31, 2016, compared to $313,932 for the year

ended December 31, 2015. Our primary use of operating cash flows from continuing

operating activities was from net losses of $451,060 and $536,130 for the years ended

December 31, 2016 and 2015, respectively. Additional contributing factors to the change

were from a decrease in prepaid expenses of $119,961, and an increase in accounts

payable and accrued expenses of $187,034. Net cash used in discontinued operating

activities was $132,131 for the year ended December 31, 2016 and net cash provided by

discontinued operations was $358,839 for the year ended December 31, 2015. Cash used

in discontinued operations for the year ended December 31, 2016 consisted of $1,990,490

in revenue from our ArcMail subsidiary and $180,849 in cash payments received from

VHT Inc. pursuant to the VHT Purchase Agreement. Cash provided by discontinued

operations for the year ended December 31, 2015 consisted of $495,930 in cash payments

received from VHT Inc. pursuant to the VHT Purchase Agreement.

Cash used in investing activities was $9,990 for the year ended December 31, 2016

and cash provided by investing activities was $1,828 for the year ended December 31,

2015\. For the year ended December 31, 2016 the primary source of cash from investing

activities was from an increase in note receivable of $15,000. For the year ended

December 31, 2015 the primary source of cash from investing activities was from a

decrease in deposits of $10,413.

Cash provided by financing activities was $172,444 for the year ended December

31, 2016 compared to cash used in financing activities of $(51,277) for the year ended

December 31, 2015. The cash flows provided by financing activities for the year ended

December 31, 2016 was primarily from proceeds from convertible debentures. The cash

flows used in financing activities for the year ended December 31, 2015 was primarily

from repayment of stockholders loans and a note payable from discontinued operations..

### Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a

combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances.

Thereafter, we expect we will need to raise additional capital and generate revenues to

meet long-term operating requirements. Additional issuances of equity or convertible

debt securities will result in dilution to our current shareholders. Further, such securities

might have rights, preferences or privileges senior to our common stock. Additional

financing may not be available upon acceptable terms, or at all. If adequate funds are not

available or are not available on acceptable terms, we may not be able to take advantage

of prospective new business endeavors or opportunities, which could significantly and

materially restrict our business operations.

### OFF BALANCE SHEET ARRANGEMENTS

We have no off balance-sheet arrangements.

## Controls and procedures

As filed, 2,577 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief

financial officer, evaluated the effectiveness of our disclosure controls and procedures

pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by

this Annual Report on Form 10-K.

Based on this evaluation, our chief executive officer and chief financial officer

concluded that, as of December 31, 2016, our disclosure controls and procedures are

designed at a reasonable assurance level and are effective to provide reasonable assurance

that information we are required to disclose in reports that we file or submit under the

Exchange Act is recorded, processed, summarized, and reported within the time periods

specified in the SEC’s rules and forms, and that such information is accumulated and

communicated to our management, including our chief executive officer and chief

financial officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that

occurred during the quarter ended December 31, 2016 that have materially affected, or

are reasonably likely to materially affect, our internal control over financial reporting.

### Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal

control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act. Our

management conducted an evaluation of the effectiveness of our internal control over

financial reporting based on the framework in Internal Control—Integrated Framework

issued by the Committee of Sponsoring Organizations of the Treadway Commission

(2013 framework). Based on this evaluation, management concluded that our internal

control over financial reporting was effective as of December 31, 2016.

**Limitations on Effectiveness of Controls and Procedure**s

In designing and evaluating the disclosure controls and procedures, management

recognizes that any controls and procedures, no matter how well designed and operated,

can provide only reasonable assurance of achieving the desired control objectives. In

addition, the design of disclosure controls and procedures must reflect the fact that there

are resource constraints and that management is required to apply its judgment in

evaluating the benefits of possible controls and procedures relative to their costs.

Filed Apr 17, 2017.
Source: SEC EDGAR, the filing index for accession 0001211524-17-000046. Last ingested by Listed: Nov 14, 2026, 12:46 ET. No prices; not investment advice.
